13d Management Lowers stake in Baxter International Inc (BAX)

Baxter International Inc (BAX) : 13d Management reduced its stake in Baxter International Inc by 20.64% during the most recent quarter end. The investment management company now holds a total of 215,991 shares of Baxter International Inc which is valued at $10,495,003 after selling 56,166 shares in Baxter International Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Baxter International Inc makes up approximately 4.35% of 13d Management’s portfolio.

Other Hedge Funds, Including , Maverick Capital Ltd sold out all of its stake in BAX during the most recent quarter. The investment firm sold 30,140 shares of BAX which is valued $1,464,503. Mengis Capital Management sold out all of its stake in BAX during the most recent quarter. The investment firm sold 10,505 shares of BAX which is valued $515,060.Janney Montgomery Scott boosted its stake in BAX in the latest quarter, The investment management firm added 3,657 additional shares and now holds a total of 32,577 shares of Baxter International Inc which is valued at $1,565,651. Baxter International Inc makes up approx 0.02% of Janney Montgomery Scott’s portfolio. Calamos Wealth Management added BAX to its portfolio by purchasing 5,239 company shares during the most recent quarter which is valued at $253,148. Baxter International Inc makes up approx 0.05% of Calamos Wealth Management’s portfolio.

Baxter International Inc closed down -0.55 points or -1.18% at $46.18 with 42,49,317 shares getting traded on Thursday. Post opening the session at $46.75, the shares hit an intraday low of $45.91 and an intraday high of $46.78 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Baxter International Inc reported $0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.40. The company had revenue of $2585.00 million for the quarter, compared to analysts expectations of $2516.16 million. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 EPS.

Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Jul 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 50 from a previous price target of $47 .Baxter International Inc was Resumed by JP Morgan to “Neutral” on Jun 6, 2016.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.

Leave a Reply

Baxter International Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxter International Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.